TMCI · Treace Medical Concepts, Inc.
Market Cap
$292.66M
Shares
65.03M
Volume · Oct 5
210.75K
Avg daily vol (3M)
338.66K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.48
Open$4.40
Day$4.24–4.54
52W close$1.20–6.95
Avg vol 30d236K
Short int1.7M · 2.7% float · 8.5d
Short vol29%
Last earningsAug 7, 2026
DataApr 2021–Oct 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Oct 27, 2026
Est · unconfirmed
· in 3 wks
filed Aug 7, 2026
call held Aug 7, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-29.9%
Trailing year
Short interest
2.7%
Latest settlement · 8.5 days to cover
AI Brief
Q1 FY26 earnings call · May 8, 2026
Q1 FY26
TL;DR. TMCI reported Q1 2026 revenue of $47.2 million, down 10% year-over-year, with net loss widening to $18.0 million, but it reaffirmed full-year 2026 revenue guidance of $202–$212 million (down 5% to 0%), driven by expected back-half acceleration from new product launches and the lapping of ASP mix headwinds.
Bullish
- + Reaffirmed full-year 2026 revenue guidance of $202–$212 million, previously raised on April 9, 2026
- + Adoption of new bunion systems grew to ~35% of Lapiplasty surgeon base in Q1 from 25% in Q4 2025
- + Mid-single-digit procedure volume growth in Q1 2026
- + Cash position grew $3.5 million sequentially to $51.9 million with ~50% reduction in full-year 2026 cash usage expected
- + Launched SuperBite Compression Screw System with successful first commercial cases, expanding TAM by ~$300 million
Bearish
- − Q1 2026 revenue declined 10% year-over-year to $47.2 million
- − Q1 2026 net loss widened to $18.0 million ($0.28/share) from $15.9 million ($0.25/share) year-over-year
- − Q1 2026 adjusted EBITDA loss deepened to $5.5 million from $3.8 million year-over-year
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+45%
above
Price vs 50-day avg
−1%
below
RSI (14)
49
neutral
MACD trend
Negative
52-week position
57%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+110%
trailing
YTD return
+83%
this year
Relative strength
+99%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +31 funds added
Insider flow
Accumulating
Net +$246.7K over 90 days · 0% sells
Short interest
Rising
2.67% of float · ▲ +11.3% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
117 holders — near 3-yr low, contrarian setup
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
Gross margin
80%
contracting
EPS growth
−3%
Y/Y
Free cash flow
$-29.5M
Balance sheet
$46.6M
net debt
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 7, 2026
Revenue
· full year 2026
Raised
$204M – $212M
May 8, 2026
$202M – $212M
changed to
Aug 7, 2026
$204M – $212M
prior FY $212.69M
midpoint −2.2% Y/Y
Reduction in cash usage
· full year 2026
Initiated
50%
Guided vs delivered
· last 4 settled
Revenue
full-year 2024
guided $201M – $211M
$209.36M
In line
Revenue
full-year 2023
guided $182M – $186M
$187.12M
Beat +1.7%
Revenue
full-year 2022
guided $135M – $138M
$141.84M
Beat +3.9%
Full year 2021 revenue
full year 2021
guided $90M – $95M
$94.42M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+45%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
57%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $3 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +31 funds added
Insider flow
Accumulating
Net +$246.7K over 90 days · 0% sells
Short interest
Rising
2.67% of float · ▲ +11.3% MoM · 8.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
117 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $4 · 57%
Range high $7
vs 200-day avg +45%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$3.5M | second quarter 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -15.87M
-445K Interest income
+1.56M Interest expense
+0K Taxes
+1.89M Depreciation & Amortization
+6.46M Share-based compensation expense
+805K Restructuring costs
+2.05M Litigation costs
= Adjusted EBITDA -3.55M
|
|||
| Gross profit margin | 78.5% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TMCI
this stock
Treace Medical Concepts, Inc.
|
$292.66M | +82.9% | +1.6% | — | 2.7% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -8.4% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -18.8% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.5% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TMCI | +0.0% | -6.9% | +110.3% | +0.9% | +82.9% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -1.2% | -7.5% | +98.8% | -0.7% | +69.2% |